Investigational Drug Abaloparatide-sc Can Help Postmenopausal Women with Osteoporosis

At the ACR/ARHP meeting, Lori Fitzpatrick, MD, explained that abaloparatide-sc can benefit postmenopausal women with osteoporosis by helping increase greater bone mineral density, since building bone strength is important for these women's health. There's also less hypercalcemia, a common side effect with other similar drugs. Fitzpatrick shared, "The approval date with the FDA is the 30th of March of next year, so we're hopeful we will be approved by the regulatory agency and hopefully be able to bring the drug to patients."